Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 4 Jan 23 424B3 Prospectus supplement
- 13 Dec 22 EFFECT Notice of effectiveness
- 12 Dec 22 424B3 Prospectus supplement
- 8 Dec 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
29 Nov 22 S-4 Registration of securities issued in business combination transactions
ADXS similar filings
- 8 Dec 22 Registration of securities issued in business combination transactions (amended)
- 29 Nov 22 Registration of securities issued in business combination transactions
- 20 Oct 21 Registration of securities issued in business combination transactions (amended)
- 13 Oct 21 Registration of securities issued in business combination transactions (amended)
- 25 Aug 21 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 28, 2022, with respect to the consolidated financial statements of Ayala Pharmaceuticals, Inc. (which contain an explanatory paragraph that describes conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), included in this Registration Statement on Form S-4 and related prospectuses of Advaxis, Inc.
/s/ Kost Forer Gabbay & Kasierer | |
A Member of Ernst & Young Global | |
Tel-Aviv, Israel | |
November 29, 2022 |